Chimerix (NASDAQ:CMRX) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.09, Fidelity Earnings reports. The business had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $0.97 million. Chimerix had a negative net margin of 1,582.64% and a negative return on equity of 34.94%.
Shares of NASDAQ CMRX traded down $0.17 during midday trading on Friday, reaching $3.32. 84,193 shares of the stock were exchanged, compared to its average volume of 215,341. The stock has a market capitalization of $172.41 million, a price-to-earnings ratio of -2.20 and a beta of 1.20. Chimerix has a twelve month low of $3.11 and a twelve month high of $5.94.
A number of equities research analysts have recently commented on CMRX shares. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research note on Thursday, October 4th. Cowen reaffirmed a “hold” rating and set a $6.00 price objective on shares of Chimerix in a research note on Thursday, October 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Chimerix in a research note on Friday, September 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $6.75.
Chimerix Company Profile
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Further Reading: Reverse Stock Split
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.